635324-72-0 Usage
Uses
Used in Pharmaceutical Research:
2-(4-fluorophenyl)-6-methyl-4-(3-(trifluoromethyl)phenyl)-1,2-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(6H)-one is used as a potential lead compound for the development of new drugs due to its complex structure and the presence of various functional groups that may contribute to biological activity.
Used in Chemical Synthesis:
2-(4-fluorophenyl)-6-methyl-4-(3-(trifluoromethyl)phenyl)-1,2-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(6H)-one may be used as an intermediate in the synthesis of other complex organic molecules, particularly those that require the dihydropyridinone or dipyrazolo moieties for their structure and function.
Used in Material Science:
2-(4-fluorophenyl)-6-methyl-4-(3-(trifluoromethyl)phenyl)-1,2-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(6H)-one's lipophilic nature and potential reactivity could make it a candidate for use in the development of new materials with specific properties, such as in the fields of polymer chemistry or as a component in the creation of new catalysts.
Note: The specific applications mentioned above are speculative based on the compound's structure and the presence of certain functional groups. Further research and experimentation would be required to confirm these potential uses and to explore additional applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 635324-72-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,5,3,2 and 4 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 635324-72:
(8*6)+(7*3)+(6*5)+(5*3)+(4*2)+(3*4)+(2*7)+(1*2)=150
150 % 10 = 0
So 635324-72-0 is a valid CAS Registry Number.
635324-72-0Relevant academic research and scientific papers
Dihydrodipyrazolopyridinone inhibitors of B7-1
-
Page 8,9, (2010/02/05)
The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease.
Structure-activity studies of a series of dipyrazolo[3,4-b:3′,4′-d]pyridin-3-ones binding to the immune regulatory protein B7.1
Green, Neal J.,Xiang, Jason,Chen, Jing,Chen, Lihren,Davies, Audrey M.,Erbe, Dave,Tam, Steve,Tobin, James F.
, p. 2991 - 3013 (2007/10/03)
The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. Herein, we report the identification of potent small molecule inhibitors of the B7.1-CD28 interaction. In a high-throughput screen we identified several leads that prevented the interaction of B7.1 with CD28 with activities in the nanomolar to low micromolar range. One of these, the dihydrodipyrazolopyridinone 1, was subsequently shown to bind the V-like domain of human B7.1 at equimolar stoichiometry. With this as a starting point, we report here the synthesis and initial in vitro structure-activity relationships of a series of these compounds.
